Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Orion InfusionsDHA:ORIONINFU +0.10%81 Return-on-Tangible-Equity is 6.77% as of Mar. 2026, which is 50% below its 10-year median of 13.45. GuruFocus rates DHA:ORIONINFU with a GF Score™ of 81/100 and a GF Value™ of BDT316.17 (Fairly Valued). The stock has 3 warning signs investors should review. Among 901 Drug Manufacturers companies, Orion Infusions ranks better than 58.93% on this metric.
Return-on-Tangible-Equity is calculated as Net Income divided by its average total shareholder tangible equity. Total shareholder tangible equity equals to Total Stockholders Equity minus Intangible Assets. Orion Infusions's annualized net income for the quarter that ended in Mar. 2026 was BDT22.1 Mil. Orion Infusions's average shareholder tangible equity for the quarter that ended in Mar. 2026 was BDT326.9 Mil. Therefore, Orion Infusions's annualized Return-on-Tangible-Equity for the quarter that ended in Mar. 2026 was 6.77%.
The historical rank and industry rank for Orion Infusions's Return-on-Tangible-Equity or its related term are showing as below:
DHA:ORIONINFU'
s Return-on-Tangible-Equity Range Over the Past 10 Years
Min: 10.63 Med: 13.45 Max: 47.37
Current: 10.84
During the past 13 years, Orion Infusions's highest Return-on-Tangible-Equity was 47.37%. The lowest was 10.63%. And the median was 13.45%.
DHA:ORIONINFU's Return-on-Tangible-Equity is ranked better than 58.93% of 901
companies
in the Drug Manufacturers industry
Industry Median: 7.9
vs DHA:ORIONINFU: 10.84
Return-on-Tangible-Equity measures the rate of return on the ownership interest (shareholder's tangible equity) of the common stock owners. It measures a firm's efficiency at generating profits from every unit of shareholders' tangible equity (shareholders equity minus intangibles). Return-on-Tangible-Equity shows how well a company uses investment funds to generate earnings growth. Return-on-Tangible-Equitys between 15% and 20% are considered desirable.
Be Aware
Net Income is used.
Because a company can increase its Return-on-Tangible-Equity by having more financial leverage, it is important to watch the leverage ratio when investing in high Return-on-Tangible-Equity companies. Like Return-on-Tangible-Asset, Return-on-Tangible-Equity is calculated with only 12 months data. Fluctuations in company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.
Asset light businesses require very few assets to generate very high earnings. Their Return-on-Tangible-Equitys can be extremely high.
Orion Infusions Return-on-Tangible-Equity Related Terms
Orion Infusions Return-on-Tangible-Equity Historical Data
* Premium members only.
The historical data trend for Orion Infusions's Return-on-Tangible-Equity can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
DHA:ORIONINFU vs ZTS, UTHR, VTRS: Return-on-Tangible-Equity Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Orion Infusions's Return-on-Tangible-Equity, along with its competitors' market caps and Return-on-Tangible-Equity data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Orion Infusions Return-on-Tangible-Equity vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Orion Infusions's Return-on-Tangible-Equity distribution charts can be found below:
* The bar in red indicates where Orion Infusions's Return-on-Tangible-Equity falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Return-on-Tangible-Equity, the net income of the last fiscal year and the average total shareholder tangible equity over the fiscal year are used. In calculating the quarterly data,
the net income data used here is four times the quarterly (Mar. 2026) net income data.
Return-on-Tangible-Equity is displayed in the 10-year financial page.
What does a Return-on-Tangible-Equity of 6.77% mean?
Orion Infusions (DHA:ORIONINFU) has a Return-on-Tangible-Equity of 6.77% as of Mar. 2026. Return on tangible equity is the ratio of current-period net income to average two-period tangible equity. View historical data on Orion Infusions and its competitors. This is 50% below median its historical median of 13.45. Over the past decade, Orion Infusions' Return-on-Tangible-Equity has ranged from 10.63 to 47.37. According to the industry distribution chart, Orion Infusions ranks #370 out of 901 companies in the Drug Manufacturers industry, placing it in the top 41.1%.
Is Orion Infusions' Return-on-Tangible-Equity too high?
Orion Infusions' current Return-on-Tangible-Equity of 6.77% is 50% below median its 10-year median of 13.45. Over the past 10 years, this metric has ranged from a low of 10.63 to a high of 47.37. The Drug Manufacturers industry median Return-on-Tangible-Equity is 7.90. Orion Infusions' value of 6.77% is 14.3% below this industry median. Based on the distribution chart, Orion Infusions ranks #370 out of 901 companies in the Drug Manufacturers industry, which is above the industry midpoint. Overall, Orion Infusions has a GF Score™ of 81/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Orion Infusions' Return-on-Tangible-Equity compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Orion Infusions ranks #370 out of 901 companies for Return-on-Tangible-Equity. This puts Orion Infusions in the upper half of its industry. The industry median Return-on-Tangible-Equity is 7.90. Orion Infusions' value of 6.77% is 14.3% below this benchmark. Historically, Orion Infusions' own Return-on-Tangible-Equity has ranged from 10.63 to 47.37 over the past decade. While the company's 10-year median is 13.45 vs. the industry median of 7.90, Orion Infusions has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Return-on-Tangible-Equity for a Drug Manufacturers company?
The median Return-on-Tangible-Equity among Drug Manufacturers companies is 7.90, based on 901 companies in the industry. Companies in the top quartile (top 25%) have a Return-on-Tangible-Equity significantly above this median, while those in the bottom quartile fall well below. However, Return-on-Tangible-Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Orion Infusions's current Return-on-Tangible-Equity of 6.77% is 14.3% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Return-on-Tangible-Equity mean?
A high Return-on-Tangible-Equity can signal that a stock is expensive relative to its fundamentals. Return on tangible equity is the ratio of current-period net income to average two-period tangible equity. View historical data on Orion Infusions and its competitors. For the Drug Manufacturers industry, the median Return-on-Tangible-Equity is 7.90 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Orion Infusions's current Return-on-Tangible-Equity is 6.77%, which is 50% below median its own 10-year median of 13.45. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Orion Infusions stock overvalued right now?
Based on GuruFocus' analysis, Orion Infusions (DHA:ORIONINFU) is currently considered Fairly Valued. The stock's GF Value™ is BDT316.17, compared to a current price of BDT291.20 — trading 7.9% below its estimated fair value. The current Return-on-Tangible-Equity is 6.77%, which is 50% below median its 10-year median of 13.45 and 14.3% below the Drug Manufacturers industry median of 7.90. Orion Infusions' overall GF Score™ is 81/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Return-on-Tangible-Equity calculated?
Return-on-Tangible-Equity is calculated from a company's financial statements. For Orion Infusions (DHA:ORIONINFU), the current Return-on-Tangible-Equity is 6.77% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Orion Infusions (DHA:ORIONINFU) Overvalued in 2026?
Based on GuruFocus' analysis, Orion Infusions stock appears to be undervalued.
The current stock price of BDT291.20 is trading 7.9% below its estimated GF Value™ of BDT316.17.
GuruFocus considers Orion Infusions to be Fairly Valued.
Key valuation signals for DHA:ORIONINFU:
Return-on-Tangible-Equity: 6.77% (50% below median its 10-year median of 13.45)
GF Value™: BDT316.17 vs. price of BDT291.20 (7.9% below fair value)
Industry Position: 14.3% below the Drug Manufacturers median (#370 of 901)
No single metric tells the full story. See the DHA:ORIONINFU stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Orion Infusions Ltd is a pharmaceutical company engaged in the production of various types of intravenous fluids, rehydration solutions, electrolyte solutions, and solutions for acidosis, as well as Ranitidine I.V. infusion and anti-microbial products such as Ciprofloxacin I.V. and Metronidazole I.V. The Company's products include Dextrolac, Dextropac, Dextrosal, Dianak, Electro Dex, Fructose, Hartman, Intralipid, Manisol, Maprocin, Nidazyl, Orlev, Ortac, Plasmasol, Proliv, and Salpac. In addition, the Group operates across several sectors, including pharma and healthcare, power and energy, infrastructure development, real estate, cosmetics and toiletries, consumer products, textiles and garments, and home appliances. Geographically, the Company operates in Bangladesh.
81GF Score
Get the complete analysis for DHA:ORIONINFU
Return-on-Tangible-Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
DHA:ORIONINFU has been successfully added to your 
